The serotonin receptor and transporter as potential therapeutic targets for pulmonary hypertension

Current Opinion in Investigational Drugs

Volumn 5, Issue 9, 2004, Pages 963-966

  Wang, Huai Liang ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

Author keywords

5 HT1B receptor; Pulmonary hypertension; Serotonin; Serotonin transporter

Indexed keywords

CARRIER PROTEIN; MEMBRANE PROTEIN; NERVE PROTEIN; SEROTONIN; SEROTONIN 1B RECEPTOR; SEROTONIN RECEPTOR; SEROTONIN TRANSPORTER; SLC6A4 PROTEIN, HUMAN;

ANIMAL; DRUG EFFECT; DRUG POTENTIATION; HUMAN; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY; PULMONARY HYPERTENSION; REVIEW;

ANIMALS; DRUG SYNERGISM; HUMANS; HYPERTENSION, PULMONARY; MEMBRANE GLYCOPROTEINS; MEMBRANE TRANSPORT PROTEINS; NERVE TISSUE PROTEINS; RECEPTOR, SEROTONIN, 5-HT1B; RECEPTORS, SEROTONIN; SEROTONIN; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS;

EID: 16644398461     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (32)

1. Von Eular US, Lilijestrand G: Observation on the pulmonary arterial blood pressure in the cat. Acta Physiol Scand (1947) 12:301-320.
2. Janssens SP, Stefan PJ, Thompson BT, Spence CR, Hales CA: Functional and structural changes with hypoxia in pulmonary circulation of spontaneously hypertensive rats. J Appl Physiol (1994) 77(3):1101-1107.
3. Wang H-L: Pharmacology on pulmonary circulation. In: Cardiovascular Pharmacology. Chen X (Ed), People's Health Press, Beijing, China (2002):373-3378.
4. Ran PX, Duan SF: The effects of persantine on pulmonary artery pressure of rats exposed to hypoxia. Chinese J Tuberc Respir Dis (1993) 16(4):252-253.
5. Hart CM, Block ER: Lung serotonin metabolism. Clin Chest Med (1989) 10(1):59-70.
6. Egermayer P, Town GI, Peacock AJ: Role of serotonin in the pathogenesis of acute and chronic pulmonary hypertension. Thorax (1999) 54(2):161-168.
7. MacLean MR: Endothelin-1 and serotonin: Mediators of primary and secondary pulmonary hypertension. J Lab Clin Med (1999) 134(2):105-114.
8. Sibbald W, Peters S, Lindsay RM: Serotonin and pulmonary hypertension in human septic ARDS. Crit Care Med (1980) 8(9):490-494.
9. Wang H-L, Liu KJ, Zhang XH, Jin X, Xing J: Effect of tetrandrine on monocrotaline-induced pulmonary hypertension in the rat. Acta Pharm Sinica (1997) 18:400-404.
10. Wang H-L, Liu KJ, Zhang XH, Jin X, Xing J: Tetrandrine inhibits chronic "inflammatory" pulmonary hypertension in rats. Drug Dev Res (1997) 39:159-160.
11. Kanai Y, Hori S, Tanaka T, Yasuoka M, Watanabe K, Aikawa N, Hosoda Y: Role of 5-hydroxytryptamine in the progression of monocrotaline induced pulmonary hypertension in rats. Cardiovasc Res (1993) 27(9):1619-1623.
12. Langleben D, Carvalho AC, Reid LM: The platelet inhibitor, dazmergrel, does not reduce monocrotaline-induced pulmonary hypertension. Am Rev Respir Dis (1986) 133(5):789-791.
13. Baguley BC, Zhuang L, Kestell P: Increased plasma serotonin following treatment with flavone-8-acetic acid, 5,6-dimethylxanthenone-4-acetic acid, vinblastine and colchicine: Reaction to vascular effects. Oncol Res (1997) 9(2):55-60.
14. Gao SH, Wang HL, Li Z, Tao HL: Effect of sumatriptan on pulmonary artery smooth muscle cells proliferation in rats. Chin J Pharmacol Toxicol (2003) 17(4):262-265.
15. 1B- receptors. Br J Chin Pharmacol (1998) 46(6):577-582.
16. lB receptors coupled to a Gi-protein. Nature (1988) 335(6187):254-256.
17. Ishizuka J, Beauchamp RD, Townsend CM Jr, Greeley GH Jr, Thompson JC: Receptor-mediated autocrine growth-stimulatory effect of 5-hydroxytryptamine on human pancreatic carcinoid cells. J Cell Physiol (1992)150(1):1-7.
18. 1-like receptor-mediated vasoconstriction in human pulmonary artery. Br J Pharmacol (1996) 119(2):277-282.
19. 1Da serotonin receptor gene expression in trigeminal ganglia: Implications for antimigraine drug development. Proc Natl Acad Sci USA (1994) 91(9):3666-3669.
20. 1B receptor augmented 5-HT vasoconstrictor response of pulmonary artery in monocrotaline-induced pulmonary hypertensive rats. Acta Pharmacol Sinica (2001) 22(3):269-273.
21. 1D receptor messenger RNA and ligand binding sites in guinea-pig brain and trigeminal ganglion: Clues for function. Neuroscience (1998) 82(2):469-484.
22. MacLean MR, Sweeney G, Baird M, McCulloch KM, Houslay M, Morecroft I: 5-Hydroxytryptamine receptors mediating vasoconstriction in pulmonary arteries from control and pulmonary hypertensive rats. Br J Pharmacol (1996) 119(5):917-930.
23. Eddahibi S, Raffestin B, Pham I, Launay JM, Aegerter P, Sitbon M, Adnot S: Treatment with 5-HT potentiates development of pulmonary hypertension in chronically hypoxic rats. Am J Physiol (1997) 272(3Pt2):H1173- H1181.
24. 1B receptor. Br J Pharmacol (1999) 128(3):730-734.
25. Ullmer C, Schmuck K, Kalkman HO, Lubbert H: Expression of serotonin receptor mRNAs in blood vessels. FEBS Lett (1995) 370(3):215-221.
26. MacLean MR: Pulmonary hypertension, anorexigens and 5-HT: Pharmacological synergism in action? Trends Pharmacol Sci (1999) 20(12):490-495.
27. Roth RA, Ganey PE: Platelets and the puzzles of pulmonary pyrolizidine poisoning. Toxicol Appl Pharmacol (1988) 93(3):463-471.
28. Hosoda Y: Pathology of pulmonary hypertension: A human and experimental study. Pathol Int (1994) 44(4):241-267.
29. Miyata M, Ito M, Sasajima T, Ohira H, Sato Y, Kasukawa R: Development of monocrotaline-induced pulmonary hypertension is attenuated by a serotonin receptor antagonist. Lung (2000) 178(2):63-73.
30. Ramamoorthy S, Bauman AL, Moore KR, Han H, Yang-Feng T, Chang AS, Ganopathy V, Blakely RD: Antidepressant- and cocaine-sensitive human serotonin transporter: Molecular cloning, expression, and chromosomal localization. Proc Natl Acad Sci USA (1993) 90(6):2542-2546.
31. Eddahibi S, Hanoun N, Lanfumey L, Lesch KP, Raffestin B, Hamon M, Adnot S: Attenuated hypoxic pulmonary hypertension in mice lacking the 5-hydroxytryptamine transporter gene. J Clin Invest (2000) 105(11):1555-1562.
32. Marcos E, Adnot S, Pham MH, Nosjean A, Raffestin B, Hamon M, Eddahibi S: Serotonin transporter inhibitors protect against hypoxic pulmonary hypertension. Am J Respir Crit Care Med (2003) 168(4):487-493.